Open AccessLong-term management of orbital and systemic reactive lymphoid hyperplasia with rituximab
Author(s) -
Aiyin Chen,
Thomas N. Hwang,
Laura Phan,
Timothy J. McCulley,
Michael K. Yoon
Publication year - 2012
Publication title -
middle east african journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.357
H-Index - 25
eISSN - 0975-1599
pISSN - 0974-9233
DOI - 10.4103/0974-9233.102770
Subject(s) - rituximab , medicine , lymphoid hyperplasia , cd20 , monoclonal antibody , monoclonal , disease , hyperplasia , oncology , immunology , lymphoma , antibody
Rituximab, a monoclonal antibody to the B cell marker CD20, is becoming increasingly popular in the treatment of various orbital disorders. In this university-based interventional case series, we describe two patients with bilateral orbital and extra-orbital reactive lymphoid hyperplasia (RLH) treated with rituximab. Initially both had favorable responses; but roughly a year later recurrent disease necessitated maintenance therapy in both cases. Both again responded to additional courses of rituximab. Although recalcitrant disease may persist after treatment, rituxmab may play a role in the management of RLH with widespread involvement.